Fidelity Investments
CLDI icon

Fidelity Investments’s Calidi Biotherapeutics CLDI Stock Holding History

Fidelity Investments’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16
Closed -$61 – 5593
2026
Q1 		$61 Sell
16
-1,360
-99% -$16.3K ﹤0.01% 5284
2025
Q4 		$25.8K Buy
1,376
+1,368
+17,100% +$32.2K ﹤0.01% 4368
2025
Q3 		$190 Buy
+8
New +$544 ﹤0.01% 5158
2024
Q4 		– Sell
-1
Closed -$161 – 5596
2024
Q3 		$161 Buy
+1
New +$278 ﹤0.01% 5051

Other funds holding CLDI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Fidelity Investments's CLDI Position: Q2 2026 in Review

Fidelity Investments sold out of Calidi Biotherapeutics (CLDI) in Q2 2026, closing a stake of 16 shares — an estimated $61 sold.

Fidelity Investments first reported a position in CLDI in Q3 2024 and held it in 4 quarters. The position peaked at $25.8K in Q4 2025. 22 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

  • Fidelity Investments reported no remaining Calidi Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Fidelity Investments sold 16 Calidi Biotherapeutics shares in Q2 2026, an estimated $61.
  • Fidelity Investments first reported a position in Calidi Biotherapeutics in Q3 2024 and held it in 4 quarters.
  • Fidelity Investments's Calidi Biotherapeutics position peaked at $25.8K in Q4 2025.
  • 22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.